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ilR service and meaical attention in the event Ih ih oL/
sickness,"216 which necessarily includes access toAstergtoliespedcednhatter
dicines.27 Thus, States are obligated to ensuretohahhsbenifrdfomheigto f
-ess to medicines as an integral component and atcltdi nvra n einlhmnr
rivative right28 of the full guarantee of the right isrmns h udmna riuaino
health.rihtolfanthrihtohatisatcae
e right to health is broadly inclusive of "a wide teUieslDcaaino ua 
ihs4
ige of socio-economic factors" and appliesfudmnahmnrittoleisefime
all social determinants of health .29 ThesethIneaiolCvnntnCvlad ll
terminants of health include all "systems put Rgt.3Tergtt iei iial rtce
place to deal with illness."30 Thus, States must teAeia n uoe 4I h fia e
sure that health care systems and infrastructure tergtt iei rtce ncnucinwt
thin their jurisdictions function to guarantee the poeto feeypro' nert.4
ht to health, including access to medicines, ford
people. Health care systems and infrastructure,
SState laws and policies, that hinder or otherwiser
trict access to medicines undermine a necessary olgtdt nueeeypro' ih opy,
terminant of health and thereby violate thean metliegty46nadtonofr(
arantee of the right to health.31frmtrueadilramn.4Frhroe
rthermore, even States not party to the ICESCR prhbtoagistrueisnaslt,
obligated to guarantee the right to health and the
rvative right of access to medicines as codified inpuihalncdtsotrue.4
vesl2and regional human rights instruments.3
ie right to health is explicitly articulated through Weeapro a esbett ilto
rmative frameworks in each of the three regionalthipysclomealnegtorubc
rnan rights systems. In the Americas, States must a c ftrueo l-ramnapro'
arantee every person's right to preserve their health t elh n hi eiaiergto ce
cluding through medical care),'34 in order that they meinssiplctdadStsar bg,
ty enjoy the highest level of well-being.35 States srie n eiie.5
ist provide primary health care, and related services
d education, to all people in their jurisdiction,ThRitsoEqatyndN -Dcrmain
luding high-risk and vulnerable individuals.36 Sae r biae ogaateeultete
ites' duties include the provision of "[u]niversalalpesnudrthlw 1dtorvntndrl
rnunization against principal infectious diseases" dsrmnto gis niiul rcmuii
d the "[p]revention and treatment of endemic, Sc rhbto gis iciiainic
cupational and other diseases."37 Similarly, in thethswomaoheiefcedcrinit
kican region, States must guarantee every person'sstgaitonnaceigthrrgttoelh
ght to enjoy the best attainable state of physicalacestmdinsbsdupnhirelh at
d mental health.",38 States must take all "necessary
asures to protect the health of their people and to Tut urne h ih ohat n h ei
fa a pssbl eidmi, ndmirn ote
11ne1log 1 toLg
As te rghtto ife s pediate on ealh, heJ
tohat a ee nerdfo tergtt i
ariclte n nvesl ndrginlp1anr
Jntuens 11fnamna a1claino
rihrolieadterih o elhi atc1t
thrnvr  elrtino ua ihs4
fudaeta umn ihttlf is rafrme
theAmricsadErp.4I h fia e
thpihtt ie spoece n ojntinwt
prtcinorvr esnsitgiy4
Th1ihstoItgiy n pae ramn
Beodpoecino h rgtt1ieSae r
I ne lignt to Social Securitytoesrthtalprosubctotei ndcir
States must ensure the social security of persons underine lahvecestonfrtonegdn!
their jurisdiction, and specifically, to assure theirhelhathcranmdinsndbeftro
economic, cultural and social rights.57 Social security rsac n eeomn eadn rvnai
must, at a rmmnmum, ensure support for individualshelhcrtamnsndeiie.
who due to age or disability may be physically or
mentally unable to meet their needs.58iR
As it applies to the right to health, the right to Sae r biae oesr vr esnsrgtt
social security requires States "to guarantee that
health systems are established to provide adequate piaeadohrnnsaeatr ovoae
access to health services for all.",59 Thus, the right tootewsfalotkencsrymsustoptd
social security "encompasses the right to access ... apro' ih olfitgiy uaetete
without discrimination in order to secure protection o te udmna ua ihicuigt
... from ... unaffordable access to health care."60rihtoeahantedrvtveigtfacssi
Furthermore, the right to social security includesr
provision of adequate access to preventive and t fetv 
eey6
curative measures, including medicines.61BStat utatdut d t
Coupled with State obligations to ensure equality me hi ea biain fgaaten h
and non-discrimination, States must thereforerihtoeahantedrvtveigtf cs,
ensure that their social security systems guarantee t
equal access, inter alia, to health care services Sae utstsyfu eeso uist ette
and medicines for all persons subject to their gtta gt
jurisdiction, specifically for those persons who rset h uyt rtctedt opooe n
would otherwise be unable to meet their health care tedt oflil6 hs uisapyt l ihi
and medicines needs. 62 bt hs htaecvladpltcl n hs h
The Right to a Healthy Environmentt
States are also obligated to ensure safe and healthy t oprt nodrt nuetefl urne
environments, including working and livingalhu nritsfrllpoe.7
environments, for all persons, which meet their
nutritional and social needs, and promote theirThDuytRepc
611
physical, emotional and intellectual development.63 edt orsetrqiesta ttsntitre
Much as the right to life is predicated on the right to i h nomn fprosrgtadrsette
health, the right to health is predicated on safe and atnm n iet srgrstereooi
healthy working and living environments. Violationssoiladctul ghS7"Tebiainb
of the requisite right to a healthy environment pr
implicate the right to health as well; such violationsStesoabaifrmpfrinpnoigc
may involve remedies via guarantees of the right totoeaignypcieolyorealmsu
health and access to medicines.viltnthinertofndiuasr fign4!
thepo rightrtorenjoy theubenefits oftscientific an
inerla aencest norainrgri
hel1 eat aean eiinsinrenftfo
1rvt adohr 1o-tt acost1voae
g persnrigttie intgityuaetete
metjhirlea obiaiifgaatenh
rih ohat adtedrvtvergto ce
respect requires states to retrai rom measures tinal icc r vial- rmt h ainlueo
negatively interfere with, or otherwise limit or deny, mdcns hog ramn udlnsbsdo
access to medicines for individuals or communities.75
Thus, the duty to respect access to medicines includes,hihpcefoneddmiiesnbthheulc
inter alia, refraining from any measures that "[deny adpiaescos hog rmto feut
or limit] equal access to medicines for [vulnerableprcninwchteoraentrquedopya
or] marginalized individuals or communities;dipootnaemutofhirncefracs;
[prohibit or impede] the use of traditional medicinesenuetamdilprctoesadptetshv
and healing practices that are scientifically sound andredacsstrlibcoptenduisd
medically appropriate; [interfere] with the provision ifraino h aeyadefcc fmdcns
of humanitarian aid that facilitates the supply ofstmleanproecmeiinnelcul
necessary medicines; [or that implement] intellectualpretycosmrrtcinadohrlwso
property policies that do not take full advantage of allprmtaceso dins.8
flexibilities in the WTO Agreement on Trade RelatedFutemrSasmstnuethtxiig
Aspects of Intellectual Property that promote access mdcnsaeaalbe cesbe cetbe n
to affordable medicines, including entering "TRIPSofgdqult85Saemstnurthtxiig
Plus" free trade agreements."76 mdcnsae"vial nsfiin uniy 8
The Duties to Protect and Promote Sae utesr htmdcnsaepyial n
The duty to protect requires States "to prevent the eooial cesbe8 ttsms 
nueta
violation of any individual's rights by any otherbecluayacptleithrpaeofdsiuin.
individual or non-State actor."77 Thus, the duty LslSae utesr rvso fgo ult
to protect requires States to implement effective mdcns ~. eiie htaentcne-e
legislation to prevent violations and effective b h cetfccmuiy xieo tews
remedies to address violations that occur. 78 nae8
The duty to protect is also intertwined with the duty
to promote, which requires States to take positive TeDt oF~l
measures to promote "tolerance, raising awareness Tedt oflilrqie ttst netk
and [infrastructural developments]" to ensure thatpoivemaustwrdthfllelztonf
people can exercise their rights and freedoms. 79 tergtt elhadtedrvtv ih facs
Correspondingly, under the duty to protect,tomdcns9Thduyoflilispefcay
States must take positive measures to prevent tigrdwee"te esrshv o ucee
discrimination. 80 i nuigtefl elzto fteergt.9
Pursuant to the duty to protect, States must ensure, Ideti uy"opie hs ciemaue
inter alia, that non-state actors, such as privatebyaGvrmnnesaytogrneeac
corporations, do not act to hinder or obstruct the pro ihnisjrsito potnte 
ohv
enjoyment of the right to health, including thefulacstolleilmnstocnmcoil
derivative right of access to medicines.81 States must adclua ihsta antb eue hog
take "[ilmmediate steps to ensure that violations" not ecuieyproa 
fot.9
only by State agents, but also by non-state actors, areThsdtenalierla locinofn
prevented.82 thus, States.mus also-guarntee-acces
e~irnayaeaaae;pooenernnlueo
1isroprint mutor hericm o ces
1 nueta ia rciinr n ainshv
1ed est eibe opeeadubae
inomto1ntesft adefcc fmdcns
1tmlt n rmt opttoitleta
drpry osmrpoeto n te ast
promte cces tomediine."8
FutemrSatsms nuerhteitn
mediine ar avalabe, ccesibl, aceptble an
ofgorult.5 ttsms nur1ht itn
medciesrre "avilbl in sfiin1 qatt.8
Sttsms1nueta edcnsaepyial n
ecnmclyacsil.7rttsms nueta
kvial eiie etmdclehc tnad n
beclualyacptbei1herpae fdsriuin8
Latyirtsms nue rvso fgo ult




The duty o fulfillrqie ttstnetk
poiiemaueroad h ulraiaino
terg tohatw n h eivtv ih facs
tomdcns9rh uyt ufl sseiial
trgeeJhee"te eaue aeno1ucee
in nsui  th flleaiaio othsrihs.9
kIndeed, thsdt1 cmrssthsciemaue
byr Grnmn eesrogaateec
pesnwti1t uidcto potnte ohv

























A. In the context of the right to health and
access to medicines, the duty to protect
puts States under the obligation to regulate
pharmaceutical companies.
In the context of the right to health and ac
medicines, States are responsible for regi
the conduct of pharmaceutical companies so
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As demonstrated in the example above, outsideIVMO TRNGADCOU ABLI
monitoring can be effective in compellingOFSAEANNN-T EAC RSO
pharmaceutical companies to act with regard ESR CEST EIIE
to their human rights responsibilities. AlthoughUnethrittoeahStsae imil
some pharmaceutical companies are making somerepnilfomntrngacsto edie,-
positive strides on their own, there is still a need hwvrnnSaeatr lohv epniiii
for State organized monitoring and accountability i hsrgr.'Mntrn scnrlt
mechanisms to assess whether pharmaceuticalStt'sdytoflilhergtohathndh
companies are actually refraining from interfering porsieraiaino h ih ohat.14T
with States' obligation to protect. gaateacutbltmntrn losol
Monitoring and accountability require me hi biain ne h ih ohat.1
benchmarking, which enhances transparencyAlhuhteWrdHahOgniton( O
among pharmaceutical companies' practices, and adteMlenu eeomn rjc a
motivates a change in their actions.maentbeporsindvlig ayic
As stipulated in General Comment 14, monitoringfrmwkstmeueacssomdinsuc
requires creating and assessing benchmarks. 159wokmsbedntoipvevauietol.16
There has been a growing trend to not just benchmark peet oioigadacutblt ehns
State practice, but also to benchmark pharmaceutical aedfcetbcueteei ooeain
companies' practices in order to assess their dfnto facs omdcn,17n rmwr
performance regarding access to medicines, and mntrn eiieacs nacutyo co
to provide tools for improvement. 160 In regards cutis 6 notnil aasotg,19a
to the benefits that benchmarking pharmaceuticalabecofqntaivtrgsadcmimns,1
companies could trigger, it is critically important toanaliteudrsnigofheikgs twi
ensure that such a practice can be made successful.meineacsadthbrdrhunrgtsla
Five different steps have been proposed to this end: (1) faeok 7
"6an initial diagnosis of a company['s] performance";-A ato hi adts ohl ttsadohr
(2) "6a defined benchmark framework"; (3) an ipoehat ucmsadt epcpoet n"6analysis of the firms selected"; (4) "the definitionfuilthrgttoeahPHanteUNSca
of improvement objectives by partners"; and (5) Rpotu oteRgtHat hudecua
"6application of the benchmark[] results." 161bohSaeannn-teacrsoetblh i
C. Because ensuring access to medicines is aimrvmotrngadcouablymehis
shared responsibility, cooperation is needed to wihrsetoacssomdcns.12Ateedc
achieve sustainable results in realizing the right to teppr eofrahmnrgt arxt vla
health and its derivative right to access medicines.thrittoeahantedrvtveigto cs
To improve access to medicines, all relevantchlegsratdomnirngndcouabi)
stakeholders should express a shared commitment, btcnetaie eiieacs ihnt
contribute their own skills and resources, cooperate withbraehunritsfmwokndpcfcll
each other despite diverging interests, and strengthen eautshwaSaei ufligisolgto
accountability and transparency mechanisms. 162 A +- - -- 1 -
As wll sbeng bliatedto rotet te rght o halt
of is ctizns y reulaingphamaceticl cmpaies
repnsbefo oitrn acestJmdcn
p r rogesv elzto frh ih ohat.6
gurnerconaiiy mntrn losol
acopnidb oneuncsfrths hofir
meetther obigaionsundr th riht t helth
Alhog th ol elhOraiain(H





pspr ftermnae ohl ttsadohr
imroe eathotcme ad o epetprteta
1ufl h ih ohatPH n h NSei
Raprert1h1 h Hat hudecua
pohSae n o-tt ars oetbiha
1mrv otngadacutblt ehns
wihrsettoacs omeiie.7iA h n
th1aew1fe uanrgt arxt vla
ph ih ohat n h eiaiergtt ce
are obligated to monitor ac
s, cooperate at the internati
ollection, and allow and enco
eipation of non-State actors


















B. Non-State actors shat
onitoring of access to i
Ite environments















































C. Monitoring access to medicines requires
disaggregating data and formulating appropriate
indicators and benchmarks, and also should
c der standardizing indicators and
identifying good practices.






































that is easy to obtain. 210 With respect Sttisfetocoewhevrmhdsolnga
to medicine access, these indicators thyrfetsmdgeeopors.ASaehsa
consider whether "key structures, sys- duytadpthsmeurshtaemotfeci,
tems and mechanisms" are in place to whltaigitaconreuceviabiyad
allow for greater access to medicines otehuaritscndrtos.23Tswn
in a State 211 (e.g., whether the State has mntrn cest eiiei siprtv
constitutionalized the right to health, or toieifandsemaeifrainongd
whether compulsory licensing provi- patcsta a etaserdt te etns 2
sions for pharmaceuticals have been in- Godpatcsilueawoiisndrgam
corporated into national legislation) .212 thtipoeacstomdinrcgiz
b) Process indicators reflect the imple- vleal rus n r ossetwt h
mentation environment and measure the ejyeto te ua 
ihs 2
extent of activities necessary to realize Stnadzdiertoalnicosaeimrat
human rights. 213 With regards to access toteporsieeaztonfthrgttoelh
to medicines, they evaluate the degree of anthdeitvergtoacssomdcns
activities that are necessary to improve beasthylowfrcs-ouryomrin,
access to medicines and the progress cutvtgraetrnpecyadiflneSaeso
of those activities over time 214 (e.g., is cletbte aaadipoemdcn ces 2
right to health is justiciable; how is the Wt eadt cest eiiesadrie
211
national strategy implemented).215ctr nda prtonldfntono cest
c) Outcome indicators measure enjoyment mdcnsaelcig 
2
11
of a human right.21 In this case, outcome D oioigi o ufcet a cossol
indicators evaluate the availability, ac- b edacutbe
cessibility, acceptability, and quality of T raeamaigu ytmo conaiiy
medicines. 217 To evaluate outcome indica-
tors with respect to medicines, household moirngsulbecpedwtisig
surveys are useful for providing informa- cosqeesfrtsewoaitomtthr
tion on how drug policies affect access and obiaon.28Udrteigtohalal
individual wellbeing. 218 prosadgop h r itm frgtt
enchmarks: Under the right to health, settingredis Coeqncsfrvlaosmy
,enchmarks and indicators is necessary to momitor ataemnfosicungpliasca,
Itate's progress in expanding access to medicines. 219 adamnsrtvbtas hudhv ea
hus far, benchmarks have not been effective with cmoet 3 uhta h ilto fargti
-spect to access to medicines. 220 States and othermewihtefreo a.3
-levant actors should set realistic benchmarks that
ave been assigned a numerical value and are time- Acrigy ea ehnss ohdmsi
12 n nerainl sol edeeoern
ound.22 Quantitative benchmarks, however, shouldsteghndohldbdaorwterhy
.ot distract attention from addressing systematic and b ttso o-tt cos conal o
11eyrefetsm ereo rges tt a
duty to adoptothose measuresqthat areumostseffective
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gbiain.28Udrth ih1o elh l
per nsandgrops h  tt
helt viltosms1aeacestprpit
remeies229 nsqueces or iolaion ma
takem n fomsincudig plitcal soial




E. In conclusion, States are primarily responsible
for monitoring access to medicines, but non-
State actors also have responsibilities in thisp
respect. Monitoring alone is insufficient. To t nraeacs omdcns 3 u
ensure accountability, monitoring should be
coupled with consequences for those who fal to acutblt ehnsst nueta
meet their obligations under the right to health. meinsismpodadttther
V. CONCLUSIONi
The right to health, and the derivative right of accessarobitetogrneeheihtoh
to medicines, is based on the fundamental human acs omdcns o l esn uj
rights enshrined in the Universal Declaration ofjuidconaswlastesreht
Human Rights, re-affirmed in the Internationalr
Covenant on Economic, Cultural and Social Rights,juidconatoicrsecestom-
and articulated in numerous other international andthtalcorhidinortewsevl,
regional human rights instruments. 233 While States fnaetlrgt r edacutbe
































by the Report of the UN Special Rapp
ly realizing the derivative right to access .o h ih ohelh(e eto































































































the ealiatin oftheRigh to implementation of all aspects of the right to health and the derivative
Healh211right to access medicine?268
(PF) (P) If yes, how does the monitoring body evaluate the level of
access to medicine in a population? Must include:
" Disaggregate data?269
" Include benchmarks and structural, process, outcome
indicators?270
21. (S) Is there a way for an individual citizen to report complaints
regarding access to medicine?271
* If so, describe the complaint mechanism.
22. (P) Does the State cooperate at the international level in data
collection related to the right to health and/or derivative right to
access medicine?272
23. (P) Does the State encourage the participation of civic society in
data collection and the monitoring of medicines?273
Availability: (S/P) Does the State have the structures and processes in place
State does everything reasonable ensuring the availability of drugs that includes the following
to ensure that existing medicines components:





















family, in dn . ei alcr...") Inentoaroeato cnmc o i nd CluaRgtat 21,Dc 6
1966 99 U..T.. 3 ereiaftr IESC (mnda ng hat"SttesParies o te peset Cvennt rcogizetherigt 6o
Convention on Hu~rnRgtatlNv 2 99
I.L. . 67 [hreinfterArrericn Covenion assetin
discrimination ~ ~ ~ ~ ~ ~ "N agis oe ntefedo elhcaei n
its enir pouainteSaemahoetorto3t
irripose three different 
types of ob igations 
on States: the
ob igations to respect, 
protect and fu fi .
Fai ure to perforrri
any one of these three 
ob igations constitutes 
a vio ation of
ote
30, art. 24 ("A peop es sha 
have the right to a genera
satisfactory environtrient favourab e to their deve oprrient.").
* See, e.g, anju Charter, supra note 30, art. 22 ("A
peop es sha have the right to 
their econorrtic. socia and
cu tura deve oprrient with due regard to their freedorri
and identity and in the equa enjoyrrient of the corrirrion
heritage of mankind. States shall have the duty, individually
or co ective y, to ensure the exercise of the right to
deve opment."); art. 21(1) (dec aring a peop es' right to
"free y dispose of their wea th and natura resources" in
accordance 
with their own interests).
6 See, e.g, Ban u Charter, supra note 30, art. 9 (dec aring
everyone's r ght to receive information).
66 See, e.g, Protoco of San Sa vador, spra note 30, art.
14(1)(b) (recognizing 
everyone's right to 
enjoy the benefits
of scientific and techno ogica progress).
* See UDHR, supra note 17, art. 8 ("Everyone has the
right to an effective 
remedy by the competent 
nat onal
tribuna s for acts vio ating the fundamenta rights granted
him by the constitution 
or by aw.")
See UN ESCR Handbook. infra note 71, at 17; see also
discussion 21- 23 (aff rming the State duty to protect
and provide remedy where rights are vio ated). See, e.g.,
European Convention, so pra note 30, art. 13 ("Everyone
whose rights and freedoms as set forth in this Convention
are vio ated sha have an effective remedy before a nationa
authority notwithstanding that the vio ation has been
committed by persons acting in an of cia capacity.") See
also, e.g, CAT, spra note 45, art. 14 1) ("Each State Party
sha ensure in its ega system that the victi of an act of
torture obtains redress and has an enforceab e right to fair
and adequate compensation, inc uding the means for as fu
rehabi itation as possib e. In the event of the death of the
victim as a resu t of an act of torture, his dependents sha
be ent t ed to compensation.")
6 Maastricht Guidelines, spra note 28, 6 ("Like civi
and po itica rights, economic, socia and cu tura rights
impose three different 
types of ob igations 
on States:
the ob igations to respect, protect and fu f . Fai ure to
perform any one of 
these three ob gations 
constitutes a
vio ation of such rights."). Genera Comment 14 to ICESCR
Art ce 12 (regarding the right to hea th) provides the most
comprehensive ana ysis 
of these duties as they 
pertain to the
rights to hea th and 
access to medicines. 
See also General





See ACHPR/Res.141 (XXXXIIII)08: Reso ution on
Access to Hea th and needed Medicines in Africa (Nov. 24,
2008) [hereinafter ACHPR 141 ; Genera Corrirrient 14,
supra note 17, 1 34.
the app ication of some rights can be made justicitib e
immed ate y whi e other rights can become justiciab e over
time.") hereinafter Li burg Princ p es . See, e.g, SERAC,
supra note 70, 46 (articu 
ating the State's duty 
"to protect
right-ho ders against 
other subjects by egis 
ation and
provision of effective 
remedies. This ob 
igation requires
the State to ta e measures to protect beneficiaries of the
protected rights against 
po itica , economic 
and social
interferences. Protection genera y entai s the creation and
maintenance of an atmosphere or framework by an effective
interp ay of aws and regu ations so that individua s wi be
rib e to free y rea ize their rights and freedoms.").
* See SER AC, supra note 70, 46.
so See UN ESCR Handbook. supra note 71, at 17. See also
Maastricht Guidelines. supra note 28, 8 (emphasizing that
" States cannot use the 'progressive rea ization' provisions
in artic e 2 of the ICESCR as a pretext for non-comp iance
nor can States ustify dero ations or imitations of rights
recognized in the Covenant 
because of different 
socia .
re igious and cu tura backgrounds.") .
See Genera Comment 14, supra note 17, 35
82 See UN ESCR Handbook, supra note 71, at 17.
Id.
84 ACHPR
To Maastricht Guidelines. supra note 28, 6 ("Like civil
54
Health Law & Policy Brief
ny, consent (emphasis added).
o UN Charter, supra note 93, art. 55 ("With a view to the
creation of conditions of stabi ity and we -being which are
necessary for peacefit and friend y re ations arriong nat ons
based on respect for the principe of equa rights and se f-
of stabi ity and we -being which are necessary for peacefit
and friend y re ations arriong nations based on respect
for the princ pe of equal rights and se f-determination of
peop es, the United Nations 
sha promote: higher 
standards
of iv ng, RI emp oy ent, and condit ons of economic and
socia progress and deve opment; solutions of international
economic, social, health, and related problems; and
internationa cu tura and educationa cooperation; and
universa respect for, and observance of, human rights and
Rindamenta freedoms for a without distinction as to race,
sex, anguage, or re igion.") 
(emphasis added) hereinafter
UN Charter ; id.art. 56 ("Al Members p edge themse ves
to take oint and separate action in co-operation with the
Organization for the 
achievement of the purposes 
set forth
in Artic e 55."). See also Dec aration on Princip es of
Internationa Law Concerning Friend y e ations and Co-
operation Among States 
in Accordance with 
the Charter of
the United Nations, (A/8082) Res. 2625 (XXV) (Oct. 24,
1970) hereinafter Internationa 
Cooperation Dec aration 
.
Id. ("Each State 
enjoys the r ghts 
inherent in fu
sovereignty; The territoria inte rity and po itical
ndependence of the State are inviohib e.").
Id. ("Each State has the duty to respect the persona ity of
other 
States.").
Id. ("States sha 
co-operate in the 
promotion of
universa respect for, and observance of, human rights and
ndamenta 
freedoms for a ... ").
See ICESCR, supra note 17, art. 2(1) ("Each State
arty to the present Covenant undertakes to take steps,
ndividua y and through international assistance and
co-operation, especially 
economic and technical, 
to
the maximum of its avaihib e resources, with a view to
achieving progressive y the fu rea ization of the rights
recognized in the present 
Covenant by a appropriate
means, inc udin particu ar y the adoption of e is ative
measures.") (emphasis added); Limburg Princ p es, supra
note 76, art. 26 ("'Its avai ab e resources' in art ce 2(1) of
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